Abstract:
Pure nucleic acids encoding novel receptors for bombesin-like peptides, the novel receptors themselves, and their antibodies. Also disclosed is a method of screening for a compound capable of interacting with any of these novel receptors.

Description:
STATEMENT AS TO FEDERALLY SPONSORED RESEARCH 
     This invention was made with support from the National Institute of Health (Grant No. R01-CA39237). Accordingly, the U.S. government may have certain rights in the invention. 
    
    
     FIELD OF THE INVENTION 
     The present invention relates generally to the manipulation of genetic materials, and, more particularly, to recombinant DNA procedures which make possible the identification of novel DNA sequences and polypeptides encoded thereby. 
     BACKGROUND OF THE INVENTION 
     Bombesin, a tetradecapeptide amide first isolated from the skin of the frog Bombina bombina, is a potent mitogen for mouse Swiss 3T3 fibroblast cells. It also stimulates secretion for guinea pig pancreatic acini. Bombesin-like peptides are produced and secreted by human small cell lung cancer cells and exogenously added bombesin-like peptides can stimulate the growth of human SCLC cells in vitro. Two examples of bombesin-like peptides are gastrin releasing peptide (GRP) and neuromedin B (NMB). 
     GRP is a 27 amino acid peptide amide and was first isolated from the porcine gut. The C-terminal amino acid sequence of GRP is almost identical to that of bombesin. NMB, on the other hand, is a decapeptide amide, the structure of which is almost identical to the last ten amino acids in the C-terminal region of GRP. Both GRP and NMB share high amino acid sequence homology with bombesin and indeed possess bombesin-like properties. Other bombesin-like peptides include litorin and neuromedin C (NMC). 
     Recent structure-function and DNA cloning studies demonstrate that at least two classes of receptors mediate the action of bombesin-like peptides. One class, the GRP preferring subtype (GRP receptor), has a high affinity for GRP and a low affinity for NMB, whereas the other class, the NMB-preferring subtype (NMB receptor), has a high affinity for NMB and lower affinity for GRP. Both classes of receptors are widely present both in the central nervous system and in the gastrointestinal tract. A third receptor class, the BRS-3 receptor, has recently been found in both rat testes and pregnant uteruses. Unlike the GRP and NMB receptors, none of the presently known bombesin-like peptide binds with high affinity (K d  &lt;25 nM) to the BRS-3 receptor. 
     SUMMARY OF THE INVENTION 
     We have discovered novel genes which code for receptors capable of binding to bombesin-like peptides. The term &#34;bombesin-like peptide&#34; used here and below refers to a peptide capable of binding with a K d  less than 1 μM to either the GRP receptor, the NMB receptor, the BRS-3 receptor, or to any other bombesin receptor subtypes such as the BB4 and BB5 receptors described below. Examples of bombesin-like peptides include, but are not limited to, bombesin, GRP, NMB, NMC, BB4 and BB5. 
     Accordingly, in one aspect, the invention features a pure nucleic acid (for example, genomic DNA, cDNA, or RNA) encoding a receptor for a bombesin-like peptide, the receptor including SEQ ID NO: 2, SEQ ID NO: 4, or SEQ ID NO: 6 (e.g., either as the entirety of the receptor or as a fragment thereof). In other words, a pure nucleic acid which encodes a receptor for a bobmesin-like peptide and includes SEQ ID NO: 1, SEQ ID NO: 3, or SEQ ID NO: 5; or a degenerate variant thereof embodies an aspect of this invention. 
     The invention also features a pure nucleic acid which (i) is capable of hybridizing to SEQ ID NO: 1, SEQ ID 5 NO: 3, or SEQ ID NO: 5 under a high- or a low-stringency hybridization condition; and (ii) encodes a receptor protein for a bombesin-like peptide. By &#34;low-stringency hybridization condition&#34; is meant: prehybridization in 25% formamide, 5× SSC, 25 mM potassium phosphate buffer (pH 7.4), 5× Denhardt&#39;s, and 50 μg/ml denatured salmon sperm DNA for 4-12 hours at 37° C. which is followed by hybridization for 12-24 hours at 37° C. and washing in 2× SSC containing 0.1% SDS, at 42° C.; or an equivalent thereof. By &#34;high-stringency hybridization condition&#34; is meant: prehybridization in 50% formamide, 5× SSC, 25 mM potassium phosphate buffer (pH 7.4), 5× Denhardt&#39;s, and 50 μg/ml denatured salmon sperm DNA for 4-12 hours at 37° C., which is followed by hybridization for 12-24 hours at 37° C. and washing in 2× SSC containing 0.1% SDS, at 55° C.; or an equivalent thereof. E.g., see Sambrook, et al. Molecular Cloning, A Laboratory Manual, 2nd Ed. Cold Spring Harbor Laboratory Press, New York (1989), hereby incorporated by reference. 
     In related aspects, a cell containing one of the nucleic acids mentioned above, and a vector which includes such a nucleic acid and is capable of directing expression of the peptide encoded by that nucleic acid in a vector-containing cell are also within the scope of this invention. 
     Other embodiments include a pure receptor protein encoded by a nucleic acid of this invention which is capable of binding to a bombesin-like peptide, and a pure antibody which is specific for such a receptor protein. 
     In another aspect, this invention features a method of screening for a compound capable of interacting with a receptor protein for a bombesin-like peptide, the method comprising the steps of: (i) providing a cell which expresses a receptor protein of this invention (e.g., a native cell expressing the receptor obtained from the brain tissue, a frog egg into which mRNA encoding the receptor is introduced, or a host cells into which DNA encoding the receptor protein is introduced for expression); (ii) contacting the compound with the receptor protein expressed by the cell; and (iii) detecting an interaction, if any, between the compound and the receptor protein (e.g., binding or any biochemical response as a result of the binding). 
     By &#34;pure nucleic acid&#34; is meant a nucleic acid that is free or substantially free (i.e., at least 60% by weight free) of the DNA or RNA sequences which, in the naturally-occurring genome of the organism from which the nucleic acid of the invention is derived, flank it. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector, into an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote; or which exists as a separate molecule (e.g., a cDNA or a genomic or cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences. It also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence. Chemically synthesized nucleic acids are also encompassed. 
     By &#34;protein&#34; is meant any chain of amino acids, regardless of length or post-translational modification (e.g., glycosylation or phosphorylation). 
     By &#34;pure receptor protein&#34; or &#34;pure antibody&#34; is meant a receptor protein or antibody which has been substantially separated from components which naturally accompany it, i.e., it is at least 60%, by weight, free from the proteins and naturally-occurring organic molecules with which it is naturally associated. A pure protein (i.e., a receptor protein or an antibody of this invention) may be obtained, for example, by extraction from a natural source, by expression of a recombinant nucleic acid, or by chemical synthesis. Purity can be measured by any appropriate method, e.g., those described in column chromatography, polyacrylamide gel electrophoresis, or by HPLC analysis. 
     Other features and advantages of the invention will be apparent from the following description and from the claims. 
    
    
     BRIEF DESCRIPTION OF THE DRAWINGS 
     The drawings are first briefly described. 
     FIG. 1 is a nucleotide sequence (SEQ ID NO:1) encoding the frog BB4 receptor; the encoded amino acid sequence (SEQ ID NO:2) is also shown. 
     FIG. 2 is a graph showing the responses to exogenous bombesin of Xenopus oocytes injected respectively with RNA&#39;s encoding the human GRP receptor and the frog BB4 receptor. 
    
    
     DETAILED DESCRIPTION OF THE INVENTION 
     Insertion of a DNA sequence of this invention into a vector, introduction of the recombinant vector thus obtained into a host cell, and subsequent expression of a receptor protein encoded by the inserted DNA sequence can be performed to produce that receptor protein. Such techniques are well known to a person of ordinary skill in the art, and in any event can be found in the literature, e.g., Sambrook, et al. Molecular Cloning, A Laboratory Manual, 2nd Ed. Cold Spring Harbor Laboratory Press, New York (1989), hereby incorporated by reference. Note that all nucleic acid sequences of this invention can be readily prepared by a person of ordinary skill in the art employing one or more the DNA sequences disclosed herein. 
     A receptor of this invention or its fragment (produced recombinantly, synthetically, or by conventional purification methods) can be used to generate an antibody (monoclonal or polyclonal) to be used as a diagnostic tool for detecting that receptor on cells from a given tissue, since the presence or expression level of that receptor may be related to cancer or other disorders. Of course, such an antibody can also be generated using a peptide fragment (e.g., a fragment of that receptor) which has at least one antigenic determinant that is immunologically reactive with an antigenic determinant of that receptor. Methods of generating and collecting such an antibody are well known in the art. For example, see Harlow et al., Antibodies--Laboratory Manual (1988, Cold Spring Harbor Laboratory), which is hereby incorporated by reference. 
     Conversely, any positively identified cells can be used to screen for compounds (e.g., a synthetic compound or the native ligand of that receptor) which interact with that receptor in various ways. As an example, bombesin-like peptides are produced and secreted by human small cell lung cancer cells (see BACKGROUND OF THE INVENTION above). Thus, some of the positively identified compounds (agonists or antagonists) can be used in the diagnosis or treatment of small cell lung cancer. 
     One way of detecting an interaction between a compound and the receptor of this invention is to monitor changes in intracellular calcium, as demonstrated in an actual example shown below. Alternatively, binding assays can be performed in screening for compounds which interact with the receptor. For experimental details, see von Schrenck T., et al. Am. J. Physiol. 1989; 256:G747-G758; and Moody T. W., et al., Methods Enzymol. 1989; 168:481-493, both of which are hereby incorporated by reference. 
     Without further elaboration, it is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent. The following specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. 
     Identification of novel receptors for bombesin-like peptides 
     The rat, mouse, and human GRP receptors and the human and rat NMB receptors were aligned in a manner described in Spindel, et al., Recent. Prog. Horm. Res. 1993; 48:365, 380-81, which is hereby incorporated by reference. This multiple alignment indicated certain conserved regions, based on which PCR primers and probes were prepared as tools used to look for novel receptors for bombesin-like peptides. More specifically, the following primers/probes were prepared: AT(ACT) CA(AG) CTI ACI TCI GTI GGI GTI TCI GT (SEQ ID NO: 7); (GA)TA IAG IGC (GA)AA IGG (AG)TT IAC (GA)CA IGA (GA)TT (SEQ ID NO: 8); (AC)G(ACGT) AA(AG) (AC)G(ACGT) (CT)T(ACGT) GC(ACGT) AA (SEQ ID NO: 9); and CC(ACGT) AC(GA) AA(ACGT) AC(ACGT) A(GA)(ACGT) AC (SEQ ID NO: 10). All primers/probes are written 5&#39; to 3&#39; mixed residues are shown in parentheses, and the symbol &#34;I&#34; denotes deoxyinosine. 
     Total RNA was then prepared by homogenization of frog brain (Bombina orientalis) in guanidine thiocyanate followed by centrifugation through CsCl. 5 μg total RNA was reverse transcribed with 25 pmole oligo(dT 18 ), 200 units of M-MLV reverse transcriptase (GIBCO-BRL, Gaithersburg, Md.), 5× buffer (250 mM Tris-HCl, pH 8.3; 375 mM KCl, 15 mM MgCl 2 , 50 mM DTT, 2.5 mM dNTP&#39;s) in 20 μl total volume at 37° C. for 1 hour. The entire reverse transcription was used in a 100 μl PCR reaction using 100 pmoles of SEQ ID NO: 7 and 100 pmoles of SEQ ID NO: 8. PCR conditions consisted of one cycle at 92° C.×2 min, 55° C.×2 min, 72° C.×3 min for second strand synthesis, followed by 35 cycles of 92° C.×40 sec, 55° C.×1 min, 72° C.×2 min. A 20 μl-aliquot of this reaction was separated on a 1% agarose gel, transferred to a Nylon membrane and hybridized to two  32  P-end labelled internal oligonucleotide probes (SEQ ID NO: 9 and SEQ ID NO: 10). The hybridizing product was subcloned into PGEM-T vector (Promega, Madison, Wis.) and sequenced as described in Nagalla, et al., J. Biol. Chem. 1992; 267:6916-22, which is hereby incorporated by reference. 
     Sequence analysis of multiple clones revealed a nucleotide sequence corresponding to position 585-position 1178 of SEQ ID NO: 1, which encoded amino acid sequence corresponding to position 132-position 329 of SEQ ID NO: 2. Both SEQ ID NO: 1 and 2 are shown in FIG. 1. The homology of the encoded amino acid sequence with the GRP, NMB and BRS-3 receptors was analyzed. The encoded amino acid sequence showed a 70.7% homology with the BRS-3 receptor, a 61.1% homology with the GRP receptor, and a 51.1% homology with the NMB receptor. These results suggested that this newly discovered encoded amino acid sequence represented a new receptor subtype, which is designated as frog BB4 receptor. To prove that this receptor was not the GRP or NMB receptor, other clones were isolated from frog stomach, brain and skin mRNA that had higher (&gt;80% homology) with their mammalian counterparts. 
     A cDNA library was next constructed from B. orientalis brain in the vector λZAP II (Stratagene, Inc., La Jolla, Calif.) using reagents and protocols provided by the supplier. To screen the cDNA library, a  32  P-labeled cRNA probe was prepared from the nucleotide sequence which corresponds to position 585-position 1178 of SEQ ID NO: 1 using the T7 promoter in the PGEM-T vector. A hybridizing clone was isolated and found to encode the full coding sequence of the Bombina orientalis BB4 receptor. See SEQ ID NO: 1 and 2 in FIG. 1. As will be set forth below, functional studies showed that frog BB4 receptor potently responded to bombesin, suggesting that this new receptor represents the prototype receptor for the bombesin/ranatensin branch of the bombesin-like peptides and is different from the BRS-3 receptor which does not respond to bombesin. 
     The cDNA encoding the frog BB4 receptor was then used to screen a monkey brain cDNA library (purchased from Clontech, Inc., Palo Alto, Calif.) at low stringency (25% formamide, 5× SSC, 37° C. with washing at 50° C. in 2× SSC). Multiple hybridizing clones were isolated. Sequence analysis of the clones revealed two subtypes with partial sequences: monkey BB4 (SEQ ID NO: 3) and monkey BB5 (SEQ ID NO: 5), which encode SEQ ID NO: 4 and SEQ ID NO: 6, respectively. Monkey BB4 appears highly homologous to frog BB4, i.e., an 88.1% homology in the 84 amino acid overlap. SEQ ID NO: 3, 4, 5 and 6 are shown below: 
     
         CAGACATCTG ACGCGGTGTT GAAGACGTGC GGCAAAGCTG TTTGTGTTTG GATTATCTCC ATGCTACTTG CTGCCCCTGA GGCAGTGTTT TCGGATTTGT ATGAATTCAC CAGCCCTGAC AAGAATATGT CCTTCAAAAC ATGTGCCCCT TATCCTGTTT CTGAAAAGCT ACTGCAAGAG ACACATTCGC TGATGTGCTT CTTAGTGTTC TATATTATTC CCTTGTCTAT TATCTCCGCC TACTACTTCC TC                                             SEQ ID NO: 3 
    
     
         Gln Thr Ser Asp Ala Val Leu Lys Thr Cys Gly Lys Ala Val Cys Val Trp Ile Ile Ser Met Leu Leu Ala Ala Pro Glu Ala Val Phe Ser Asp Leu Tyr Glu Phe Thr Ser Pro Asp Lys Asn Met Ser Phe Lys Thr Cys Ala Pro Tyr Pro Val Ser Glu Lys Leu Leu Gln Glu Thr His Ser Leu Met Cys Phe Leu Val Phe Tyr Ile Ile Pro Leu Ser Ile Ile Ser Ala Tyr Tyr Phe Leu               SEQ ID NO: 4 
    
     
         CAGACCTCAG ATGCTGTGCT GAAGACCTGT GCCAAAGCTG GTGGCATCTG GATCATGGCT ATGATATTTG CTCTGCCAGA GGCTATATTC TCAAATGTAT ACACTTTCCA AGGTCCTAAC AGAAACGTAA CATTTGAATC CTGTAACTCC TACCCTATCT CTGAGAGGCT TTTGCAGGAA ATACATTCTC TGTTGTGTTT CTTGGTGTTC TACATTATCC CGCTCTCGAT TATCTCCGCC TATTACTTCC                                                SEQ ID NO: 5 
    
     
         Gln Thr Ser Asp Ala Val Leu Lys Thr Cys Ala Lys Ala Gly Gly Ile Trp Ile Met Ala Met Ile Phe Ala Leu Pro Glu Ala Ile Phe Ser Asn Val Tyr Thr Phe Gln Gly Pro Asn Arg Asn Val Thr Phe Glu Ser Cys Asn Set Tyr Pro Ile Ser GluArg Leu Leu Gln Glu Ile His Ser Leu Leu Cys Phe Leu Val Phe Tyr Ile Ile Pro Leu Ser Ile Ile Ser Ala Tyr Tyr Phe                       SEQ ID NO: 6 
    
     Function studies (changes in intracellular calcium) 
     To prepare the receptor RNA for injection into Xenopus oocytes, the linearized cDNA encoding frog BB4 receptor, was phenol extracted, ethanol precipitated, and then transcribed with T7 or T3 RNA polymerase. Transcription reactions were carried out in a 50-100 μl volume containing 5-20 μg DNA template, 40 mM Tris (pH 7.9), 7 mM MgCl 2 , 10 mM DTT, 2 mM spermidine, 10 mM NaCl, 25 μg/ml BSA, 0.5 mM ATP, 0.5 mM UTP, 0.5 mM CTP, 0.2 mM GTP, 1 mM 7-Me GpppG (Pharmacia, Piscataway, N.J.), 50-100 units RNA polymerase and 125-250 units RNasin (Promega, Madison, Wis.). The reactions were incubated at 40° C. for 90 minutes, treated with FPLC purified DNase (Pharmacia, Piscataway, N.J.), phenol extracted twice, ethanol precipitated twice, and then resuspended in 5-10 μl H 2  O. See Julius, et al. Science 1988; 241:558-564, which is hereby incorporated by reference. 
     To measure bombesin-induced changes in intracellular calcium, the procedure described in Sandberg, et al. FEBS Lett 1988; 241:177-180 (hereby incorporated by reference) was followed with some modifications (see Spindel, et al., Mol. Endocrinol. 1990; 4:1956-1963; and Giladi, et al., Biotechniques 1991; 10:744-747) to determine, both of which are hereby incorproated by reference). More specifically, oocytes were removed from an albino Xenopus, treated with collagenase, defollicated, and then injected in the presence of OR-2 (a buffer solution suitable for frog oocytes) without calcium. The injection needles were rinsed with 1 mM EDTA before each use. For injection, the transcribed RNA (typically, 1-2 μl) was dried down and then suspended in an equal volume of an aequorin solution. The aequorin solution was prepared at a concentration of 1 mg/ml in 1 mM EDTA and stored in aliquots at -85° C. Aequorin was obtained from Friday Harbor Photoproteins, Friday Harbor, Wash. 
     To record the bombesin-induced response, oocytes were placed in 500 μl OR-2 in 12×55 mm disposable polystyrene tubes in a luminometer. Light output from the oocyte as recorded by the luminometer is a function of ligand-induced increases in intracellular calcium. The baseline response to OR-2 was first recorded, followed by the recording of the response to bombesin. 
     As a positive control, Xenopus oocytes containing exogenous human GRP receptor were also prepared and assayed in analogous manners. 
     FIG. 2 demonstrates the respective responses of GRP and BB4 receptors to 1 nM (in the OR-2 buffer) of bombesin. It is clear that the BB4 receptor, unlike the BRS-3 receptor, potently responded to bombesin. 
     OTHER EMBODIMENTS 
     From the above description, one skilled in the art can easily ascertain the essential characteristics of the present invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, other embodiments are also within the claims. 
     For example, contemplated equivalents of this invention include nucleic acid or peptide sequences which are substantially identical to those clearly described above and explicitly claimed below. By &#34;substantially identical&#34; is meant a nucleic acid or peptide exhibiting at least 50%, preferably 85%, more preferably 90%, and most preferably 95% homology to a reference amino acid or nucleic acid sequence. For peptides, the length of comparison sequences will generally be at least 16 amino acids, preferably at least 20 amino acids, more preferably at least 25 amino acids, and most preferably 35 amino acids. For nucleic acids, the length of comparison sequences will generally be at least 50 nucleotides, preferably at least 60 nucleotides, more preferably at least 75 nucleotides, and most preferably 110 nucleotides. 
     Sequence identity is typically measured using sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705). Such software matches similar sequences by assigning degrees of homology to various substitutions, deletions, substitutions, and other modifications. Conservative substitutions typically include substitutions within the following groups: (i) glycine, alanine; (ii) valine, isoleucine, leucine; (iii) aspartic acid, glutamic acid, asparagine, glutamine; (iv) serine, threonine; (v) lysine, arginine; and (vi) phenylalanine, tyrosine. 
     Furthermore, nucleic acide and peptides which are allelic variations, natural mutants, and induced mutants are also within the scope of this invention. 
     Still other contemplated equivalents of this invention include peptides which are shorter than a receptor of this invention (e.g., a fragment thereof) which has at least one antigenic determinant that is immunologically reactive with an antigenic determinant of that receptor. 
     Other embodiments are also within the claims set forth below. 
     
         __________________________________________________________________________SEQUENCE LISTING(1) GENERAL INFORMATION:(iii) NUMBER OF SEQUENCES: 10(2) INFORMATION FOR SEQ ID NO: 1:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 1563(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:CACGAGTGCAAGCACTAAACCACCCTAGTGCTGATGAGAGCTGTGATTTCTGGAGATACC60GAGTTTGTGGACATCAATTAGGTTTCATTTGTGGAACTTTAATTGAGGTCACTTGTGTGC120TGCAATTCATGAACTTGAAACTGCTGAAGAAGAAATTTGGAACAACTGAATTTTATTTAG180ATTAAAAAAAAATGCCTGAAGGTTTTCAGTCACTTAACCAGACATTGCCA230MetProGluGlyPheGlnSerLeuAsnGlnThrLeuPro1510TCTGCTATAAGTAGCATAGCTCATTTGGAATCCCTTAATGACAGTTTC278SerAlaIleSerSerIleAlaHisLeuGluSerLeuAsnAspSerPhe152025ATTTTAGGTGCAAAGCAAAGTGAAGATGTATCCCCTGGGTTAGAAATA326IleLeuGlyAlaLysGlnSerGluAspValSerProGlyLeuGluIle30354045CTGGCTCTAATTTCTGTCACATATGCTGTTATTATTTCTGTCGGTATC374LeuAlaLeuIleSerValThrTyrAlaValIleIleSerValGlyIle505560CTTGGAAACACAATACTTATAAAAGTATTTTTTAAAATCAAGTCAATG422LeuGlyAsnThrIleLeuIleLysValPhePheLysIleLysSerMet657075CAGACTGTTCCTAATATTTTCATCACCAGCCTGGCTTTTGGAGATCTT470GlnThrValProAsnIlePheIleThrSerLeuAlaPheGlyAspLeu808590CTTCTACTGCTGACCTGCGTGCCAGTGGACGCATCTCGGTATATTGTG518LeuLeuLeuLeuThrCysValProValAspAlaSerArgTyrIleVal95100105GACACGTGGATGTTTGGAAGAGCTGGCTGTAAGATAATTTCCTTCATA566AspThrTrpMetPheGlyArgAlaGlyCysLysIleIleSerPheIle110115120125CAGCTTACCTCTGTCGGAGTGTCGGTGTTTACTTTAACTGTCCTCAGT614GlnLeuThrSerValGlyValSerValPheThrLeuThrValLeuSer130135140ACTGACAGGTACAGAGCCATTGTGAAACCCTTGCAATTGCAGACCTCA662ThrAspArgTyrArgAlaIleValLysProLeuGlnLeuGlnThrSer145150155GATGCCGTTTTGAAGACATGTGGCAAAGCTGTTTGTGTTTGGATCATT710AspAlaValLeuLysThrCysGlyLysAlaValCysValTrpIleIle160165170TCCATGCTCCTCGCTGCTCCAGAAGCTGTGTTCTCAGATTTGTATGAA758SerMetLeuLeuAlaAlaProGluAlaValPheSerAspLeuTyrGlu175180185TTTGGCAGCTCGGAAAAAAATACCACTTTTGAAGCCTGTGCTCCATAT806PheGlySerSerGluLysAsnThrThrPheGluAlaCysAlaProTyr190195200205CCAGTCTCTGAAAAGATTCTGCAAGAGACACATTCCCTAATATGCTTC854ProValSerGluLysIleLeuGlnGluThrHisSerLeuIleCysPhe210215220CTGGTATTCTACATTGTTCCCCTGTCAATCATTTCTGCATATTACTTC902LeuValPheTyrIleValProLeuSerIleIleSerAlaTyrTyrPhe225230235CTTATTGCAAAAACCCTGTACAAAAGTACTTTCAACATGCCTGCTGAA950LeuIleAlaLysThrLeuTyrLysSerThrPheAsnMetProAlaGlu240245250GAGCACACTCACGCCCGAAAACAGATAGAATCGCGCAAACGAGTGGCA998GluHisThrHisAlaArgLysGlnIleGluSerArgLysArgValAla255260265AAAACTGTGTTGGTGTTGGTGGCATTGTTCGCAGTGTGCTGGTTGCCA1046LysThrValLeuValLeuValAlaLeuPheAlaValCysTrpLeuPro270275280285AACCACATGCTCTACTTGTATCGATCCTTCACATATCACTCCGCAGTG1094AsnHisMetLeuTyrLeuTyrArgSerPheThrTyrHisSerAlaVal290295300AATTCCTCTGCGTTTCACCTGTCAGCCACAATCTTTGCGCGAGTACTG1142AsnSerSerAlaPheHisLeuSerAlaThrIlePheAlaArgValLeu305310315GCTTTGCGCAATTCCTGCGTCAACCCCTTCGCCCTCTATTGGCTAAGC1190AlaLeuArgAsnSerCysValAsnProPheAlaLeuTyrTrpLeuSer320325330AAGAGCTTTAGGCAGCATTTTAAAAAGCAAGTGTATTGTTGTAAGACT1238ArgSerPheArgGlnHisPheLysLysGlnValTyrCysCysLysThr335340345GAACCTCTGCATCCAACAAAGTCCGACCCACAGCAGTACCATAACTGG1286GluProLeuHisProThrLysSerAspProGlnGlnTyrHisAsnTrp350355360365AATTACCGCTGTGAAAGGCAACATCCAGATGTCTGAAATTAGC1329AsnTyrArgCysGluArgGlnHisProAspVal370375ATTACATTATTAAGTGCTTACGATGTAAAGAAAGAGTGACAGTGTCGCCAAATAAGTTAT1389AAAAAGTTTATAAAACTTACTGTAAACAAAAGATGGATAAAGTTTTTGTTGCTGCATATT1449GACGTCTGTTTATTAAAAATCCAGAGTATAAAGTTTTATTACTACAAACAAAAAAATATA1509CCTCAACATTCTAACCACAATTGAATTATTCATATATTACCCTTATTTATTCAG1563(2) INFORMATION FOR SEQ ID NO: 2:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 376(B) TYPE: amino acid(C) STRANDEDNESS: single(D) TOPOLOGY: Not Relevant(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:MetProGluGlyPheGlnSerLeuAsnGlnThrLeuProSerAlaIle151015SerSerIleAlaHisLeuGluSerLeuAsnAspSerPheIleLeuGly202530AlaLysGlnSerGluAspValSerProGlyLeuGluIleLeuAlaLeu354045IleSerValThrTyrAlaValIleIleSerValGlyIleLeuGlyAsn505560ThrIleLeuIleLysValPhePheLysIleLysSerMetGlnThrVal65707580ProAsnIlePheIleThrSerLeuAlaPheGlyAspLeuLeuLeuLeu859095LeuThrCysValProValAspAlaSerArgTyrIleValAspThrTrp100105110MetPheGlyArgAlaGlyCysLysIleIleSerPheIleGlnLeuThr115120125SerValGlyValSerValPheThrLeuThrValLeuSerThrAspArg130135140TyrArgAlaIleValLysProLeuGlnLeuGlnThrSerAspAlaVal145150155160LeuLysThrCysGlyLysAlaValCysValTrpIleIleSerMetLeu165170175LeuAlaAlaProGluAlaValPheSerAspLeuTyrGluPheGlySer180185190SerGluLysAsnThrThrPheGluAlaCysAlaProTyrProValSer195200205GluLysIleLeuGlnGluThrHisSerLeuIleCysPheLeuValPhe210215220TyrIleValProLeuSerIleIleSerAlaTyrTyrPheLeuIleAla225230235240LysThrLeuTyrLysSerThrPheAsnMetProAlaGluGluHisThr245250255HisAlaArgLysGlnIleGluSerArgLysArgValAlaLysThrVal260265270LeuValLeuValAlaLeuPheAlaValCysTrpLeuProAsnHisMet275280285LeuTyrLeuTyrArgSerPheThrTyrHisSerAlaValAsnSerSer290295300AlaPheHisLeuSerAlaThrIlePheAlaArgValLeuAlaLeuArg305310315320AsnSerCysValAsnProPheAlaLeuTyrTrpLeuSerArgSerPhe325330335ArgGlnHisPheLysLysGlnValTyrCysCysLysThrGluProLeu340345350HisProThrLysSerAspProGlnGlnTyrHisAsnTrpAsnTyrArg355360365CysGluArgGlnHisProAspVal370375(2) INFORMATION FOR SEQ ID NO: 3:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 252(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:CAGACATCTGACGCGGTGTTGAAGACGTGCGGCAAAGCTGTTTGTGTT48GlnThrSerAspAlaValLeuLysThrCysGlyLysAlaValCysVal151015TGGATTATCTCCATGCTACTTGCTGCCCCTGAGGCAGTGTTTTCGGAT96TrpIleIleSerMetLeuLeuAlaAlaProGluAlaValPheSerAsp202530TTGTATGAATTCACCAGCCCTGACAAGAATATGTCCTTCAAAACATGT144LeuTyrGluPheThrSerProAspLysAsnMetSerPheLysThrCys354045GCCCCTTATCCTGTTTCTGAAAAGCTACTGCAAGAGACACATTCGCTG192AlaProTyrProValSerGluLysLeuLeuGlnGluThrHisSerLeu505560ATGTGCTTCTTAGTGTTCTATATTATTCCCTTGTCTATTATCTCCGCC240MetCysPheLeuValPheTyrIleIleProLeuSerIleIleSerAla65707580TACTACTTCCTC252TyrTyrPheLeu84(2) INFORMATION FOR SEQ ID NO: 4:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 84(B) TYPE: amino acid(C) STRANDEDNESS: Not Relevant(D) TOPOLOGY: Not Relevant(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:GlnThrSerAspAlaValLeuLysThrCysGlyLysAlaValCysVal151015TrpIleIleSerMetLeuLeuAlaAlaProGluAlaValPheSerAsp202530LeuTyrGluPheThrSerProAspLysAsnMetSerPheLysThrCys354045AlaProTyrProValSerGluLysLeuLeuGlnGluThrHisSerLeu505560MetCysPheLeuValPheTyrIleIleProLeuSerIleIleSerAla65707580TyrTyrPheLeu84(2) INFORMATION FOR SEQ ID NO: 5:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 250(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:CAGACCTCAGATGCTGTGCTGAAGACCTGTGCCAAAGCTGGTGGCATC48GlnThrSerAspAlaValLeuLysThrCysAlaLysAlaGlyGlyIle151015TGGATCATGGCTATGATATTTGCTCTGCCAGAGGCTATATTCTCAAAT96TrpIleMetAlaMetIlePheAlaLeuProGluAlaIlePheSerAsn202530GTATACACTTTCCAAGGTCCTAACAGAAACGTAACATTTGAATCCTGT144ValTyrThrPheGlnGlyProAsnArgAsnValThrPheGluSerCys354045AACTCCTACCCTATCTCTGAGAGGCTTTTGCAGGAAATACATTCTCTG192AsnSerTyrProIleSerGluArgLeuLeuGlnGluIleHisSerLeu505560TTGTGTTTCTTGGTGTTCTACATTATCCCGCTCTCGATTATCTCCGCC240LeuCysPheLeuValPheTyrIleIleProLeuSerIleIleSerAla65707580TATTACTTCC250TyrTyrPhe83(2) INFORMATION FOR SEQ ID NO: 6:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 83(B) TYPE: amino acid(C) STRANDEDNESS: Not Relevant(D) TOPOLOGY: Not Relevant(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:GlnThrSerAspAlaValLeuLysThrCysAlaLysAlaGlyGlyIle151015TrpIleMetAlaMetIlePheAlaLeuProGluAlaIlePheSerAsn202530ValTyrThrPheGlnGlyProAsnArgAsnValThrPheGluSerCys354045AsnSerTyrProIleSerGluArgLeuLeuGlnGluIleHisSerLeu505560LeuCysPheLeuValPheTyrIleIleProLeuSerIleIleSerAla65707580TyrTyrPhe83(2) INFORMATION FOR SEQ ID NO: 7:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 29(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ix) FEATURE:(D) OTHER INFORMATION: N at each of positions 9, 12, 15,18, 21, 24 and 27 is deoxyinosine(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:ATHCARCTNACNTCNGTNGGNGTNTCNGT29(2) INFORMATION FOR SEQ ID NO: 8:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 30(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ix) FEATURE:(D) OTHER INFORMATION: N at each of positions 4, 7, 13, 19and 25 is deoxyinosine(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:RTANAGNGCRAANGGRTTNACRCANGARTT30(2) INFORMATION FOR SEQ ID NO: 9:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 17(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ix) FEATURE:(D) OTHER INFORMATION: N at each of positions 3, 9, 12 and15 is A, C, G or T(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:MGNAARMGNYTNGCNAA17(2) INFORMATION FOR SEQ ID NO: 10:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 17(B) TYPE: nucleic acid(C) STRANDEDNESS: single(D) TOPOLOGY: linear(ix) FEATURE:(D) OTHER INFORMATION: N at each of positions 3, 9, 12 and15 is A, C, G or T(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:CCNACRAANACNARNAC17__________________________________________________________________________